Neuroendocrine Malignancies: Advanced Targeted Therapy with Lutetium Lu-177 DOTATATE

Precision Care for Neuroendocrine Tumors

United Theranostics specializes in treating neuroendocrine malignancies using Lutetium Lu-177 DOTATATE, an advanced radiopharmaceutical therapy. This targeted approach delivers therapeutic radiation precisely to neuroendocrine tumor cells, improving treatment effectiveness while minimizing harm to healthy tissues.

Request An Appointment

Why Choose Lutetium Lu-177 DOTATATE Therapy?

Targeted Action: Binds to somatostatin receptors on neuroendocrine tumor cells for precise therapy.
Personalized Treatment: Care plans tailored to each patient’s unique clinical and molecular profile.
Outpatient Convenience: Most treatments are performed on an outpatient basis.
Proven Results: Demonstrated efficacy in tumor control and symptom relief for advanced neuroendocrine tumors.

How the Therapy Works

Molecular Imaging: PET or SPECT scans confirm the presence of somatostatin receptor-positive tumors.
Therapy Administration: Lutetium Lu-177 DOTATATE is administered intravenously to target tumor cells.
Targeted Radiation: Delivers a controlled dose of radiation to cancer cells, sparing healthy tissue.
Ongoing Monitoring: Regular follow-up with imaging and lab work to assess response and adjust care as needed.

Who Can Benefit?

Patients with advanced or metastatic neuroendocrine tumors that express somatostatin receptors.
Individuals seeking alternatives to chemotherapy or surgery, or those not responding to other treatments.

Frequently Asked Questions (FAQ)

B
C

What is Lutetium Lu-177 DOTATATE therapy?

Lutetium Lu-177 DOTATATE is a targeted radiopharmaceutical therapy designed for patients with neuroendocrine tumors. It delivers radiation directly to tumor cells, reducing damage to healthy tissue.
B
C

Am I eligible for this therapy?

Eligibility is determined through imaging (PET or SPECT scans) to confirm that your tumor expresses somatostatin receptors. Our team will review your medical history and imaging results to assess suitability.
B
C

What can I expect during treatment?

Treatment is typically given as an outpatient procedure. The radiopharmaceutical is administered intravenously over a short period. Most patients receive several treatment cycles spaced weeks apart.
B
C

Are there side effects?

Some patients experience mild to moderate side effects, such as nausea, fatigue, or changes in blood counts. Our team provides comprehensive support to manage any side effects and ensure your safety.
B
C

How soon can I start treatment?

There is no waiting time for new patients to begin therapy after the initial consultation and eligibility assessment.
B
C

Will my insurance cover this therapy?

United Theranostics assists with insurance verification and can help identify financial assistance programs for eligible patients.
B
C

How do I prepare for my appointment?

Our team will provide detailed instructions before each treatment session, including any dietary or medication considerations.
B
C

What follow-up is required?

Regular follow-up visits with imaging and laboratory tests are recommended to monitor your response and adjust your treatment plan as needed.

United Theranostics: Your Partner in Precision Oncology

Expertise: Multidisciplinary team with extensive experience in molecular imaging and radiopharmaceutical therapy.
Comprehensive Support: From consultation to follow-up, we guide you through every step of care.
Regional Access: Multiple locations for your convenience.

Ready to Learn More?

If you or a loved one has been diagnosed with a neuroendocrine malignancy, contact United Theranostics to learn if Lutetium Lu-177 DOTATATE therapy is right for you.